Don't Think of Corlanor as a Replacement for Beta-Blockers for Heart Failure

June 2015

Corlanor (CORE-lah-nore, ivabradine) will be the first new drug approved for systolic heart failure in a decade.

It works by inhibiting the If or "funny" current in the heart. This lowers heart rate...withOUT causing a drop in blood pressure.

Ivabradine prevents 1 in 25 patients from being hospitalized over 2 years...when ADDED to an ACEI or ARB, beta-blocker, and aldosterone antagonist. But it DOESN'T reduce overall mortality.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote